Aryl hydrocarbon receptor: A bridge linking immuno-inflammation and metabolism in atherosclerosis.
Aryl hydrocarbon receptor
Atherosclerosis
Immuno-inflammation
Metabolism
Journal
Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
26
05
2023
revised:
08
08
2023
accepted:
09
08
2023
pubmed:
15
8
2023
medline:
15
8
2023
entrez:
14
8
2023
Statut:
ppublish
Résumé
Cardiovascular disease is the leading cause of death worldwide, and atherosclerosis is a major contributor to this etiology. The ligand-activated transcription factor, known as the aryl hydrocarbon receptor (AhR), plays an essential role in the interactions between genes and the environment. In a number of human diseases, including atherosclerosis, the AhR signaling pathway has recently been shown to be aberrantly expressed and activated. It's reported that AhR can regulate the immuno-inflammatory response and metabolism pathways in atherosclerosis, potentially serving as a bridge that links these processes. In this review, we highlight the involvement of AhR in atherosclerosis. From the literature, we conclude that AhR is a potential target for controlling atherosclerosis through precise interventions.
Identifiants
pubmed: 37579858
pii: S0006-2952(23)00335-0
doi: 10.1016/j.bcp.2023.115744
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
115744Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.